An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Trial Profile

An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs RG 7386 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 30 Oct 2017 Results (data cut off: 26 Apr 2017, n=32) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 20 Jul 2017 Planned End Date changed from 26 Sep 2017 to 31 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top